Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part I

Bissery, Marie Christine; Nohynek, Gerhard J.; Sanderink, Gérard; Lavelle, François

doi:10.1097/00001813-199506000-00001

Cited by 268 publications

(187 citation statements)

References 0 publications

Supporting

Mentioning

177

Contrasting

Order By: Relevance

“…Docetaxel (Taxotere s , sanofi-aventis, Paris, France) is a semisynthetic taxoid derived from the European yew tree, Taxus baccata (Denis et al, 1990). A preclinical study of docetaxel showed a synergistic antitumour activity in combination with 5-FU (Bissery et al, 1995), which led to several clinical studies in advanced GC. In this setting, docetaxel has been evaluated both as a single agent (Sulkes et al, 1994;Einzig et al, 1996;Taguchi et al, 1998;Mai et al, 1999) and in combination with fluoropyrimidines (Constenla et al, 2002;Park et al, 2004), cisplatin (Roth et al, 2000), and cisplatin plus 5-FU (Van Custem et al, 2003).…”

mentioning

confidence: 99%

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

et al. 2006

View full text Add to dashboard Cite

The aims of this phase I/II study of docetaxel and S-1 were to determine the dose-limiting toxicity (DLT), maximum-tolerated dose (MTD), and recommended dose (RD) in the phase I part and to explore the tumour response, survival and safety in the phase II part. Patients with histologically-or cytologically confirmed unresectable or recurrent gastric cancer were eligible. Treatment consisted of intravenous docetaxel on day 1 (starting dose 50 mg m À2 ) and oral S-1 at a fixed dose of 40 mg m À2 twice daily on days 1 -14, every 4 weeks up to six cycles. Nine patients took part in the phase I portion of the study. The MTD of docetaxel was determined to be 50 mg m À2 , with the DLTs of grade 3 infection associated with grade 3 neutropenia and grade 4 neutropenia during S-1 administration. The RD of docetaxel was 40 mg m À2 in combination with S-1 40 mg m À2 b.i.d. The efficacy and safety of this regimen was therefore assessed in 46 patients with at least one measurable lesion. The overall response rate and estimated median overall survival were 46% (95% CI, 31 -61%) and 14.0 months (8.3 -17.3 months), respectively. The most common grade 3/4 toxicity was neutropenia (67% of patients), which was predictable and manageable. This regimen showed promising activity with moderate toxicities in advanced gastric cancer.

show abstract

mentioning

confidence: 99%

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

et al. 2006

View full text Add to dashboard Cite

show abstract

“…The binding affinity of docetaxel for the beta-tubulin subunit is greater than that of paclitaxel (relative potency 1.9 versus 1.0) [8][9][10]. The two drugs have subtly different binding sites: the tau site in the case of docetaxel and the N-terminal 31 amino acids in the case of paclitaxel.…”

Section: Mechanism Of Actionmentioning

confidence: 99%

“…In general, docetaxel is taken up more avidly than paclitaxel and bound more tightly. However, probably of greatest relevance to clinical activity are differences in drug efflux: docetaxel is retained intracellularly for a longer period than paclitaxel [8,14].…”

Section: Pharmacokineticsmentioning

confidence: 99%

See 1 more Smart Citation

Docetaxel: Overview of an Active Drug for Breast Cancer

Crown

2001

The Oncologist

View full text Add to dashboard Cite

show abstract

“…Paclitaxel has been evaluated as an active agent for endometrial cancer (Ball et al, 1996;Lissoni et al, 1996;Lincoln et al, 2003). However, preclinical data show that docetaxel has increased potency and an improved therapeutic index compared with paclitaxel (Bissery et al, 1995), and its short 1-h infusion time offers a substantial clinical advantage over the prolonged infusion durations required with paclitaxel. Docetaxel and paclitaxel also have substantially different toxicity profiles.…”

mentioning

confidence: 99%

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

et al. 2005

View full text Add to dashboard Cite

The purpose of this study was to determine whether docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma. Chemotherapy-naïve or previously treated patients (one regimen) with histopathologically documented endometrial carcinoma and Eastern Cooperative Oncology Group performance status p2 entered the study. Docetaxel 70 mg m À2 was administered intravenously on day 1 of a 3-week cycle up to a maximum of six cycles. If patients responded well to docetaxel, additional cycles were administered until progressive disease or unacceptable toxicity occurred. Of 33 patients with a median age of 59 years (range, 39 -74 years) who entered the study, 14 patients (42%) had received one prior chemotherapy regimen. In all, 32 patients were evaluable for efficacy, yielding an overall response rate of 31% (95% confidence interval, 16.1 -50.0%); complete response and partial response (PR) were 3 and 28%, respectively. Of 13 pretreated patients, three (23%) had a PR. The median duration of response was 1.8 months. The median time to progression was 3.9 months. The predominant toxicity was grade 3 -4 neutropenia, occurring in 94% of the patients, although febrile neutropenia arose in 9% of the patients. Oedema was mild and infrequent. Docetaxel has antitumour activity in patients with advanced or recurrent endometrial carcinoma, including those previously treated with chemotherapy; however, the effect was transient and accompanied by pronounced neutropenia in most patients.

show abstract

Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part I

Cited by 268 publications

References 0 publications

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer

Docetaxel: Overview of an Active Drug for Breast Cancer

Phase II trial of docetaxel in advanced or metastatic endometrial cancer: a Japanese Cooperative Study

Contact Info

Product

Resources

About